Contravisory Investment Management’s Biodexa Pharmaceuticals BDRX Stock Holding History

Contravisory Investment Management’s Portfolio BDRX Stock Details BDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1	Closed	-$53	–	376
2025 Q1	$53	Hold	1	–	–	﹤0.01%	372
2024 Q4	$162	Hold	1	–	–	﹤0.01%	389
2024 Q3	$282	Hold	1	–	–	﹤0.01%	342
2024 Q2	$896	Buy	+1	New	+$1.31K	﹤0.01%	342

Other funds holding BDRX

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Contravisory Investment Management's BDRX Position: Q2 2025 in Review

Contravisory Investment Management sold out of Biodexa Pharmaceuticals (BDRX) in Q2 2025, closing a stake of 1 share — an estimated $53 sold.

Contravisory Investment Management first reported a position in BDRX in Q2 2024 and held it in 4 quarters. The position peaked at $896 in Q2 2024. 4 funds tracked by Wall St. Rank hold BDRX as of Q2 2025.

Contravisory Investment Management reported no remaining Biodexa Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Contravisory Investment Management sold 1 Biodexa Pharmaceuticals share in Q2 2025, an estimated $53.
Contravisory Investment Management first reported a position in Biodexa Pharmaceuticals in Q2 2024 and held it in 4 quarters.
Contravisory Investment Management's Biodexa Pharmaceuticals position peaked at $896 in Q2 2024.
4 funds tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q2 2025.

Based on Contravisory Investment Management's 13F filing for Q2 2025, filed 10 Jul 2025.